在充满挑战的市场环境中，Myriad Genetics, Inc. (MYGN)股价触及52周新低，跌至16.6美元。这一最新价格走势反映出过去一年1.15%的温和增长，表明在更广泛的市场波动中经历了一段相对稳定的时期。投资者正密切关注公司的表现，因为股价在52周范围的低端附近波动可能表明对那些希望利用医疗保健板块动态的投资者来说既存在潜在风险也有机会。 在其他近期新闻中，Myriad Genet ...

Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...

The industry is now watching to see how this development will shape the company's financial outlook and whether other insurers will follow UNH's lead. In other recent news, Myriad Genetics has ...

Myriad Genetics (MYGN) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago. These figures ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $22.1 million in its third quarter. On a per-share basis, the Salt Lake City-based company said ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

The firm reiterated its Sector Outperform rating and a price target of $34.00 for the company's stock. The affirmation followed Myriad Genetics' Investor Day, which was held on Sunday, where the ...

周一，TD Cowen维持Myriad Genetics (NASDAQ:MYGN)股票的持有评级，目标价保持在$30.00不变。这一决定是在联合健康(UNH)最近更改药物基因检测政策之后做出的。 具体而言，UNH更新了其指南，排除了对多基因检测的覆盖，包括Myriad Genetics的GeneSight产品，该产品用于指导抗抑郁药物治疗。在这一公告之后，Myriad Genetics的股价下跌 ...

The market's response to the news has been notably negative, but it remains to be seen whether the current drop in Myriad Genetics' stock price is an overreaction or an accurate reflection of the ...